SynthesisCancer metastasis reviews2025
Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis.
Synthesis in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The objective of this study is to compare the pathological complete response (pCR) and survival rates of different neoadjuvant chemoradiotherapy modalities (NACRT) for locally advanced rectal cancer, which is defined as rectal cancer with T3-4/N + and without distant metastasis. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Chinese Society of Clinical Oncology (CSCO) for randomized controlled trials (RCTs) and late-breaking abstracts on NACRT in locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) from inception to December 2024. Eighteen articles including 11658 MSS LARC patients were included: nine articles compared concurrent oxaliplatin or irinotecan with standard chemoradiotherapy, six articles conducted total neoadjuvant chemotherapy (cTNT), and three articles integrated immunotherapy (iTNT) as the NACRT regimen. CapOX cTNT modality ranked first to achieve the best pCR. The consolidation of two cycles of CapOX/FOLFOX cTNT ranked first in achieving the best 5-year overall survival (OS) rate. The consolidation of six cycles of FOLFOX cTNT ranked first in achieving the best 5-year disease-free survival (DFS) rate. Evidence from this network meta-analysis suggests that cTNT regimens, including CapOX cTNT and mFOLFIRINOX cTNT as induction regimens, have significant benefits in achieving the best pCR rate in MSS LARC patients. According to our network analysis, iTNT was not as beneficial as cTNT in achieving the best pCR. Consolidation of cTNT has the advantage of achieving long-term survival. Adverse events (AEs) reported for most iTNT modalities appear manageable.
Indexed as
Identifiers
40699387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.